Table 1 Patient characteristics
From: Effect of relaxation therapy on benzodiazepine use in patients with medically unexplained symptoms
| Baseline | Matched-pair baseline | |||||
|---|---|---|---|---|---|---|
| Control (n = 179) | Relaxation (n = 42) | P value | Control (n = 84) | Relaxation (n = 42) | P value | |
| Sex | 0.38 | 1.00 | ||||
| Male | 75 | 14 | 28 | 14 | ||
| Female | 104 | 28 | 56 | 28 | ||
| Age (years) | 47.73 ± 15.89 | 47.80 ± 17.29 | 0.95 | 46.44 ± 17.29 | 47.80 ± 17.29 | 0.66 |
| Habit | ||||||
| Smoking | 40 | 2 | < 0.01 | 4 | 2 | 1.00 |
| Drinking | 35 | 8 | 1.00 | 16 | 8 | 1.00 |
| Education (over 16 years) | 65 | 17 | 0.72 | 31 | 17 | 0.70 |
| Marriage | 91 | 21 | 1.00 | 42 | 21 | 1.00 |
| Antidepressant | 102 | 17 | 0.06 | 34 | 17 | 1.00 |
| Benzodiazepine | ||||||
| DAPa dose (mg/month) | 150.00 | 143.35 | 0.24 | 150.00 | 143.35 | 0.76 |
| Short acting | 105 | 24 | 0.86 | 42 | 24 | 0.57 |
| Long durationb | 121 | 26 | 0.47 | 48 | 26 | 0.70 |